2023
Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
Pfeiler G, Hlauschek D, Mayer E, Deutschmann C, Kacerovsky-Strobl S, Martin M, Meisel J, Zdenkowski N, Loibl S, Balic M, Park H, Prat A, Isaacs C, Bajetta E, Balko J, Bellet-Ezquerra M, Bliss J, Burstein H, Cardoso F, Fohler H, Foukakis T, Gelmon K, Goetz M, Haddad T, Iwata H, Jassem J, Lee S, Linderholm B, Los M, Mamounas E, Miller K, Morris P, Munzone E, Gal-Yam E, Ring A, Shepherd L, Singer C, Thomssen C, Tseng L, Valagussa P, Winer E, Wolff A, Zoppoli G, Machacek-Link J, Schurmans C, Huang X, Gauthier E, Fesl C, Dueck A, DeMichele A, Gnant M, Cameron D, El-Abed S, Rugo H, Steger G, Traina T, Werutsky G, Wolmark N. Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial. Journal Of Clinical Oncology 2023, 41: 5118-5130. PMID: 37556775, DOI: 10.1200/jco.23.00126.Peer-Reviewed Original ResearchConceptsImpact of BMIPALLAS trialBMI categoriesHigher BMIEarly hormone receptor-positive breast cancerHormone receptor-positive breast cancerReceptor-positive breast cancerAddition of palbociclibEfficacy of palbociclibEarly treatment discontinuationRelative dose intensityTreatment discontinuation ratesDisease-free survivalSide effect profileMultivariable logistic regressionBreast cancer riskSignificant decreaseNeutropenia ratesPalbociclib armEndocrine therapyTreatment discontinuationDiscontinuation ratesDose intensityEarly discontinuationNormal weight
2021
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, Senn HJ, Winer EP, Gnant M, Conference P, Aebi S, André F, Barrios C, Bergh J, Bonnefoi H, Morales D, Brucker S, Burstein H, Cameron D, Cardoso F, Carey L, Chua B, Ciruelos E, Colleoni M, Curigliano G, Delaloge S, Denkert C, Dubsky P, Ejlertsen B, Fitzal F, Francis P, Galimberti V, Mahmoud H, Garber J, Gnant M, Gradishar W, Gulluoglu B, Harbeck N, Huang C, Huober J, Ilbawi A, Jiang Z, Johnston S, Lee E, Loibl S, Morrow M, Partridge A, Piccart M, Poortmans P, Prat A, Regan M, Rubio I, Rugo H, Rutgers E, Sedlmayer F, Semiglazov V, Senn H, Shao Z, Spanic T, Tesarova P, Thürlimann B, Tjulandin S, Toi M, Trudeau M, Turner N, Luis I, Viale G, Watanabe T, Weber W, Winer E, Xu B. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Annals Of Oncology 2021, 32: 1216-1235. PMID: 34242744, PMCID: PMC9906308, DOI: 10.1016/j.annonc.2021.06.023.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerBreast cancerSystemic therapyEarly breast cancerTime of diagnosisBreast cancer patientsInternational consensus guidelinesBreast cancer riskRadiation oncology providersBreast cancer diagnosisNeoadjuvant therapyMultidisciplinary careOncology providersClinical featuresConsensus guidelinesCancer patientsPatient preferencesTreatment recommendationsTreatment responseCancer riskClinical careClinical informationConsensus conferenceEarly breast cancer diagnosisPatient experience
2017
Surveillance Mammography in Older Patients With Breast Cancer—Can We Ever Stop?: A Review
Freedman RA, Keating NL, Partridge AH, Muss HB, Hurria A, Winer EP. Surveillance Mammography in Older Patients With Breast Cancer—Can We Ever Stop?: A Review. JAMA Oncology 2017, 3: 402-409. PMID: 27892991, PMCID: PMC5540165, DOI: 10.1001/jamaoncol.2016.3931.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsSurveillance mammographyAnticipated life expectancyOlder patientsBreast eventsBreast cancerCancer survivorsOlder survivorsHormonal therapyLife expectancyContralateral breast cancer riskOlder breast cancer survivorsAnnual surveillance mammographyIndividual riskPatient's individual riskCancer-related causesResidual breast tissueWomen 70 yearsBreast cancer riskBreast cancer screeningContralateral cancerMammographic surveillanceLocal therapyHealthy womenCancer screening
2015
Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women
Collins LC, Gelber S, Marotti JD, White S, Ruddy K, Brachtel EF, Schapira L, Come SE, Borges VF, Schedin P, Warner E, Wensley T, Tamimi RM, Winer EP, Partridge AH. Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women. The Oncologist 2015, 20: 713-718. PMID: 26025931, PMCID: PMC4492229, DOI: 10.1634/theoncologist.2014-0412.Peer-Reviewed Original ResearchConceptsBreast cancer molecular phenotypesBreast cancerYoung womenFamily historyPregnancy-associated breast cancerMolecular phenotypesTumor histologic gradeBreast cancer riskBreast cancer phenotypeLast pregnancyParous womenProspective cohortCentral reviewHistologic gradeLike subtypeMolecular subtypesLarge cohortCancer riskPregnancyClinical practiceStudy questionnaireBiomarker expressionCancerTumor phenotypeWomen
2011
P4-11-12: Molecular Phenotype of Breast Cancers in a Large Cohort of Young Women According to Time Interval Since Pregnancy.
Collins L, Gelber S, Marotti J, Cole K, Kereakoglow S, Ruddy K, Brachtel E, Schapira L, Come S, Borges V, Schedin P, Warner E, Winer E, Partridge A. P4-11-12: Molecular Phenotype of Breast Cancers in a Large Cohort of Young Women According to Time Interval Since Pregnancy. Cancer Research 2011, 71: p4-11-12-p4-11-12. DOI: 10.1158/0008-5472.sabcs11-p4-11-12.Peer-Reviewed Original ResearchNulliparous young womenBreast cancerYoung womenLast pregnancyParous womenNulliparous womenTumor gradeLarge cohortBreast cancer molecular phenotypesPregnancy-associated breast cancerOngoing prospective cohort studyMolecular phenotypesLuminal B cancersCentral pathology reviewProspective cohort studyMonths of diagnosisTriple-negative cancersBreast cancer riskGenomic alterationsHER2 typeParous breastPrior pregnancyB cancersCohort studyMedian age
2009
Impact of a mixed strength and endurance exercise intervention on levels of adiponectin, high molecular weight adiponectin and leptin in breast cancer survivors
Ligibel JA, Giobbie-Hurder A, Olenczuk D, Campbell N, Salinardi T, Winer EP, Mantzoros CS. Impact of a mixed strength and endurance exercise intervention on levels of adiponectin, high molecular weight adiponectin and leptin in breast cancer survivors. Cancer Causes & Control 2009, 20: 1523-1528. PMID: 19434504, DOI: 10.1007/s10552-009-9358-3.Peer-Reviewed Original ResearchConceptsHigh molecular weight adiponectinBreast cancer survivorsLevels of adiponectinMolecular weight adiponectinCancer survivorsExercise interventionWeight adiponectinOverweight breast cancer survivorsUsual care control groupEndurance exercise interventionCare control groupBreast cancer riskImpact of exerciseBody fat percentageAdipocytokine levelsExercise groupSignificant changesHip circumferenceMethodsOne hundredSignificant inverse relationshipBreast cancerAdiponectinCancer riskHip measurementsAnthropometric measurementsImpact of a home-based physical activity intervention upon exercise behaviors and anthropometric measures in women undergoing treatment for early stage breast cancer.
Ligibel J, Campbell N, Anita G, Shockro L, Salinardi T, Winer E. Impact of a home-based physical activity intervention upon exercise behaviors and anthropometric measures in women undergoing treatment for early stage breast cancer. Cancer Research 2009, 69: 1117. DOI: 10.1158/0008-5472.sabcs-1117.Peer-Reviewed Original ResearchEarly-stage breast cancerStage breast cancerHome-based exercise interventionBreast cancer patientsQuality of lifeBreast cancerWeight gainAdjuvant chemotherapyExercise interventionCancer patientsPhysical activityBody fatAnthropometric measuresHome-based physical activity interventionSingle-arm pilot studyWeek 12 valuesBreast cancer outcomesPhysical activity interventionsTime of enrollmentArm pilot studyBreast cancer riskImpact of exerciseLean muscle massBreast cancer diagnosisAdjuvant therapyPhysical Activity Behaviors in Women with Newly Diagnosed Ductal Carcinoma-In-Situ
Ligibel JA, Partridge A, Giobbie-Hurder A, Golshan M, Emmons K, Winer EP. Physical Activity Behaviors in Women with Newly Diagnosed Ductal Carcinoma-In-Situ. Annals Of Surgical Oncology 2009, 16: 106-112. PMID: 18953612, PMCID: PMC5842912, DOI: 10.1245/s10434-008-0174-x.Peer-Reviewed Original ResearchConceptsPhysical activityDuctal carcinomaTreatment-related variablesLongitudinal cohort studyStrenuous physical activityBreast cancer riskLogistic regression modelingPhysical activity behaviorType of exerciseTamoxifen useCohort studyBilateral mastectomyEpidemiological evidenceSitu cancerReconstructive surgeryCancer riskDepressive symptomsExercise levelsMost womenExercise frequencyHealth outcomesActivity behaviorWomenExercise behaviorNonsignificant variables
2008
Impact of a Mixed Strength and Endurance Exercise Intervention on Insulin Levels in Breast Cancer Survivors
Ligibel JA, Campbell N, Partridge A, Chen WY, Salinardi T, Chen H, Adloff K, Keshaviah A, Winer EP. Impact of a Mixed Strength and Endurance Exercise Intervention on Insulin Levels in Breast Cancer Survivors. Journal Of Clinical Oncology 2008, 26: 907-912. PMID: 18281663, DOI: 10.1200/jco.2007.12.7357.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsExercise groupCancer survivorsInsulin levelsExercise interventionInsulin concentrationsGlucose levelsBody compositionControl groupOverweight breast cancer survivorsUsual care control groupEndurance exercise interventionCare control groupMicroU/mLSignificant decreaseBreast cancer recurrenceBreast cancer riskBreast cancer prognosisInsulin resistanceHip circumferenceCancer recurrenceBody fatHip measurementsPhysical activityCancer riskRisk Perceptions and Psychosocial Outcomes of Women With Ductal Carcinoma In Situ: Longitudinal Results From a Cohort Study
Partridge A, Adloff K, Blood E, Dees EC, Kaelin C, Golshan M, Ligibel J, de Moor JS, Weeks J, Emmons K, Winer E. Risk Perceptions and Psychosocial Outcomes of Women With Ductal Carcinoma In Situ: Longitudinal Results From a Cohort Study. Journal Of The National Cancer Institute 2008, 100: 243-251. PMID: 18270338, DOI: 10.1093/jnci/djn010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnxietyBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingCohort StudiesDepressionFemaleHumansLogistic ModelsLongitudinal StudiesMammographyMass ScreeningMassachusettsMiddle AgedNeoplasm Recurrence, LocalOdds RatioPredictive Value of TestsPrognosisQuality of LifeRisk AssessmentRisk FactorsConceptsLocal recurrence rateRecurrence ratePsychosocial outcomesDuctal carcinomaModerate riskCancer-related risksFavorable overall prognosisSystemic recurrence ratesBreast-conserving treatmentBreast cancer riskDCIS diagnosisCohort studyDCIS recurrenceOverall prognosisDisease recurrenceInvasive cancerDCISCancer riskPsychosocial concernsHealth behaviorsEnrollment surveySubstantial anxietyWomenInaccurate perceptionsModerate likelihood
2007
Impact of physical activity on insulin levels in breast cancer survivors
Ligibel J, Campbell N, Chen H, Salinardi T, Chen W, Partridge A, Mantzoros C, Winer E. Impact of physical activity on insulin levels in breast cancer survivors. Journal Of Clinical Oncology 2007, 25: 555-555. DOI: 10.1200/jco.2007.25.18_suppl.555.Peer-Reviewed Original ResearchBreast cancer survivorsInsulin levelsPhysical activityCancer survivorsExercise groupΜIU/Glucose levelsControl groupEarly-stage breast cancerBreast cancer-related deathsBaseline insulin levelsCare control groupStage breast cancerBreast cancer recurrenceBreast cancer riskCancer-related deathBreast cancer prognosisStrength training sessionMeasurements of weightAdjuvant treatmentExercise interventionHip circumferenceInsulin sensitivityCancer recurrenceFat mass
2002
American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.
Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG, Burstein HJ, Eisen A, Lipkus I, Pfister DG. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. Journal Of Clinical Oncology 2002, 20: 3328-43. PMID: 12149307, DOI: 10.1200/jco.2002.06.029.Peer-Reviewed Original ResearchConceptsBreast cancer risk reductionUse of tamoxifenCancer risk reductionBreast cancer riskCancer riskASCO Health Services Research CommitteeBreast cancer risk reduction strategiesAromatase inhibitionCancer risk reduction strategiesClinical Oncology technology assessmentEvidence-based technology assessmentsHealth Services Research CommitteeBreast cancer-specific survivalHigher breast cancer riskUse of raloxifeneCancer-specific survivalHormone replacement therapyBreast cancer incidenceHealth benefitsGreater clinical benefitOverall health benefitsAmerican SocietyOutcomes of interestNet health benefitRisk reduction
1998
Overestimation of Hereditary Breast Cancer Risk
Iglehart J, Miron A, Rimer B, Winer E, Berry D, Shildkraut J. Overestimation of Hereditary Breast Cancer Risk. Annals Of Surgery 1998, 228: 375-384. PMID: 9742920, PMCID: PMC1191495, DOI: 10.1097/00000658-199809000-00010.Peer-Reviewed Original ResearchConceptsOvarian cancerHereditary factorsBRCA2 mutationsHereditary breast cancer riskIntensive clinical servicesTest-negative womenExpert panelBreast cancer riskCarrier probabilitiesAffected womenFamily historyCancer riskHereditary riskCancerClinical servicesBreastWomenHigher risk perceptionPretest educationWomen's perceptionsPersonal historyRiskBRCA1Disease-associated mutationsBRCA2
1997
A Review of Hereditary Breast Cancer: From Screening to Risk Factor Modification
Warmuth M, Sutton L, Winer E. A Review of Hereditary Breast Cancer: From Screening to Risk Factor Modification. The American Journal Of Medicine 1997, 102: 407-415. PMID: 9217624, DOI: 10.1016/s0002-9343(97)00093-4.Peer-Reviewed Original ResearchConceptsRisk factor modificationBreast cancerFactor modificationGenetic testingBreast cancer riskBreast cancer casesHereditary breast cancerPotential prophylactic measuresClinical managementBRCA2 mutationsCancer casesCancer riskProphylactic measuresWay patientsCancerGene mutationsGenetic mutationsGenetic testsGenetic aspectsMajor advancesBRCA1MutationsScreeningPatientsDisease